Home > Boards > US OTC > Biotechs >

Taxus Cardium Pharmaceuticals Group Inc. (CRXM)

Add CRXM Price Alert      Hide Sticky   Hide Intro
Moderator: i_like_bb_stock, doogdilinger, Papa Bear, WHITTENHALLJR, docj
Search This Board: 
Last Post: 9/17/2020 11:25:58 PM - Followers: 119 - Board type: Free - Posts Today: 0

Investment by Nostrum Pharmaceuticals LLC: https://www.otcmarkets.com/filing/html?id=14182106&guid=TmVFUWUD04P0tth

CRXM accounting firm is top notch: https://www.marcumllp.com/offices

Clinicaltrials.com update August 2020
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : June 1, 2022

Understanding refractory angina and the AFFIRM study:

Taxus Cardium Announces Name Change To Gene Biotherapeutics

January 10, 2018PR-M01-18-NI-021


SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc. 

The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs.  Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.

Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities.  Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged.  As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.

Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.

Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.

Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates.  To learn more about Angionetics visit www.angionetics.com.

As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications.  Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes.   Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.

As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CRXM News: Initial Statement of Beneficial Ownership (3) 08/17/2020 02:31:27 PM
CRXM News: Initial Statement of Beneficial Ownership (3) 08/14/2020 01:40:44 PM
CRXM News: Initial Statement of Beneficial Ownership (3) 07/08/2020 12:38:25 PM
CRXM News: Initial Statement of Beneficial Ownership (3) 07/08/2020 12:36:30 PM
CRXM News: Statement of Beneficial Ownership (sc 13d) 06/01/2020 05:33:06 PM
#2856  Sticky Note Email received yesterday. We’re in good esi23 09/15/20 11:05:36 AM
#2774  Sticky Note CRXM status for those that care to understand esi23 09/10/20 08:59:55 AM
#2716  Sticky Note An email Chris sent me a while back. docj 09/09/20 08:40:48 AM
#2563  Sticky Note Rounded up some DD for all the new HoldEm777 09/03/20 03:11:53 PM
#2878   Dip pricing, will be adding more. sharky 09/17/20 11:25:58 PM
#2877   We have got a filing every month for JJ24 09/17/20 05:32:07 PM
#2876   Yep, same here. learningthetruth 09/17/20 04:48:19 PM
#2875   Shares in my back pocket, daily don't matter. sharky 09/17/20 03:48:14 PM
#2874   Indeed $CRXM WHITTENHALLJR 09/17/20 11:12:08 AM
#2873   Yup huge Material events on the way . $CRXM$$ JJ24 09/17/20 10:19:52 AM
#2872   Agreed and coming....just a matter of when, not if. learningthetruth 09/17/20 10:09:34 AM
#2871   .09 is bottom if your looking for a WHITTENHALLJR 09/17/20 09:45:50 AM
#2870   Looking like strong hands in control now ,no JJ24 09/16/20 07:32:33 PM
#2869   If you can load and hold you will JJ24 09/16/20 11:50:04 AM
#2868   Fantastic share structure: docj 09/16/20 05:43:53 AM
#2867   Correct. Looking forward to seeing the Super 10K. docj 09/16/20 05:37:33 AM
#2866   First things first is the Super 10k..... then HoldEm777 09/15/20 10:17:59 PM
#2865   Nostrum Pharmaceuticals, LLC (“Nostrum”). Nostrum is the parent HoldEm777 09/15/20 09:46:45 PM
#2864   Was reading through the article I posted and HoldEm777 09/15/20 09:20:58 PM
#2863   Wonderful, thanks! Mjw28fan 09/15/20 08:27:01 PM
#2862   $CRXM >> + $1.00 Don’t be that guy WHITTENHALLJR 09/15/20 04:23:19 PM
#2861   Yup! Solid company! Dollar Land in our future JJ24 09/15/20 01:51:49 PM
#2860   Looking good WHITTENHALLJR 09/15/20 01:12:09 PM
#2859   Nice CPM 09/15/20 11:30:14 AM
#2858   Excellent....very close. learningthetruth 09/15/20 11:09:38 AM
#2857   Nice ! Thx for posting ! $CRXM$$ JJ24 09/15/20 11:08:29 AM
#2856   Email received yesterday. We’re in good esi23 09/15/20 11:05:36 AM
#2855   Hopefully they sell and don’t look back! JJ24 09/15/20 10:38:12 AM
#2854   Added 26k @8 WHITTENHALLJR 09/15/20 10:35:30 AM
#2853   It is amazing to think that the poor Tiger Money 09/15/20 10:10:49 AM
#2852   Yup! 1 day closer! Every $1 dollar invested JJ24 09/15/20 10:08:48 AM
#2851   Another day closer. My shares locked sharky 09/15/20 09:57:00 AM
#2850   CRXM is going to be a big one balamidas 09/15/20 09:18:13 AM
#2849   Accumulation building pressure with catalyst approaching sharky 09/14/20 08:43:24 PM
#2848   6 to 1 Buys outweighing Sells..... very nice HoldEm777 09/14/20 06:04:08 PM
#2847   Niiiice. CPM 09/14/20 02:56:45 PM
#2846   Many here are locking the float, one day sharky 09/14/20 12:29:46 PM
#2845   Grabbed some a few days ago, looking good... CPM 09/14/20 12:27:48 PM
#2844   Huge upside with news ahead IMO sharky 09/14/20 11:58:40 AM
#2843   Thanks black! Very interesting here! Eagle1 09/14/20 11:23:22 AM
#2842   We intend to file a “super 10-K” report sharky 09/14/20 10:44:56 AM
#2841   Phase 3 approaching sharky 09/14/20 10:43:55 AM
#2840   Big time indeed. GREGG THE GREEK 09/14/20 10:14:14 AM
#2839   Amen brother! Tiger Money 09/14/20 09:34:15 AM
#2838   Super 10k to get current and updates on JJ24 09/14/20 09:27:57 AM
#2837   Great research bud. I can’t wait until Tiger Money 09/14/20 09:24:07 AM
#2836   Stars are lining for CRXM !i like what balamidas 09/14/20 09:19:51 AM
#2835   Morning Balamidas. Agreed can’t be to esi23 09/14/20 09:13:42 AM
#2834   a super 10 K here is going to balamidas 09/14/20 08:47:25 AM
#2833   Been doing a little more DD on Nirmal HoldEm777 09/14/20 07:56:21 AM
#2832   Nothing new but I am posting part of docj 09/14/20 06:44:26 AM
#2831   Time to lock this one up as we HoldEm777 09/13/20 05:14:07 PM
#2830   I sent you an email. docj 09/13/20 04:23:54 PM
#2829   Very exciting times ahead (could be VERY SOON) Tiger Money 09/13/20 04:21:14 PM
Consent Preferences